These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 39281673)

  • 21. Gene Editing by Extracellular Vesicles.
    Kostyushev D; Kostyusheva A; Brezgin S; Smirnov V; Volchkova E; Lukashev A; Chulanov V
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33028045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR/Cas: Current State and Perspectives.
    Dong W; Kantor B
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring non-viral methods for the delivery of CRISPR-Cas ribonucleoprotein to hematopoietic stem cells.
    Molaei Z; Jabbarpour Z; Omidkhoda A; Ahmadbeigi N
    Stem Cell Res Ther; 2024 Jul; 15(1):233. PubMed ID: 39075609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plant Viruses: From Targets to Tools for CRISPR.
    Varanda CM; Félix MDR; Campos MD; Patanita M; Materatski P
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33478128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functionalized extracellular nanovesicles as advanced CRISPR delivery systems.
    Wang S; Kong H; Zhuo C; Liu L; Lv S; Cheng D; Lao YH; Tao Y; Li M
    Biomater Sci; 2024 Jul; 12(14):3480-3499. PubMed ID: 38808607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CRISPR/Cas9: Principle, Applications, and Delivery through Extracellular Vesicles.
    Horodecka K; Düchler M
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for
    Wei T; Cheng Q; Farbiak L; Anderson DG; Langer R; Siegwart DJ
    ACS Nano; 2020 Aug; 14(8):9243-9262. PubMed ID: 32697075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
    Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
    Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of AAV Vectors for CRISPR-Mediated In Vivo Genome Editing in the Retina.
    Yu W; Wu Z
    Methods Mol Biol; 2019; 1950():123-139. PubMed ID: 30783971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Viral Delivery Systems for CRISPR.
    Xu CL; Ruan MZC; Mahajan VB; Tsang SH
    Viruses; 2019 Jan; 11(1):. PubMed ID: 30621179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Viral Vectors for the
    Asmamaw Mengstie M
    Front Bioeng Biotechnol; 2022; 10():895713. PubMed ID: 35646852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
    Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
    Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retroviral Vectors for Cancer Gene Therapy.
    Schambach A; Morgan M
    Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical Advances in LNP-CRISPR Therapeutics for Solid Tumor Treatment.
    Wang S; Zhu Y; Du S; Zheng Y
    Cells; 2024 Mar; 13(7):. PubMed ID: 38607007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in CRISPR/Cas systems-based cell and gene therapy.
    Poddar A; Ahmady F; Prithviraj P; Luwor RB; Shukla R; Polash SA; Li H; Ramakrishna S; Kannourakis G; Jayachandran A
    Prog Mol Biol Transl Sci; 2024; 208():161-183. PubMed ID: 39266181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
    Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
    Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR Systems Suitable for Single AAV Vector Delivery.
    Stevanovic M; Piotter E; McClements ME; MacLaren RE
    Curr Gene Ther; 2022; 22(1):1-14. PubMed ID: 34620062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
    Wong TWY; Cohn RD
    Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Approach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect.
    Chuang YF; Phipps AJ; Lin FL; Hecht V; Hewitt AW; Wang PY; Liu GS
    Cell Mol Life Sci; 2021 Mar; 78(6):2683-2708. PubMed ID: 33388855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy.
    Yi K; Kong H; Lao YH; Li D; Mintz RL; Fang T; Chen G; Tao Y; Li M; Ding J
    Adv Mater; 2024 Mar; 36(13):e2300665. PubMed ID: 37437039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.